Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Medicilon
Shanghai, Shanghai, Chinaen.medicilon.com.cn ↗
- Ownership
- Private
- Employees
- ~2400
- Development stage
- Commercial
01
Overview
Shanghai Medicilon provides comprehensive preclinical contract research services covering drug discovery through IND-enabling studies. The company supports global pharmaceutical and biotech clients with integrated solutions including chemical synthesis, compound screening/optimization, structural biology research, CMC development and GMP-compliant API manufacturing. Their facilities are GLP-certified by both Chinese NMPA and US FDA. They do not develop their own drugs but enable client pipelines from early discovery to IND submission.
- Modalities
- Small moleculeBiologicAntibody-drug conjugatePROTAC technology (Proteolysis-targeting chimera therapy)DNA-encoded library screening compounds
- Industry
- Drug Discovery Services
Beyond the preview
Go deeper on Shanghai Medicilon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Medicilon.